trending Market Intelligence /marketintelligence/en/news-insights/trending/M3vf3qj997oNNOBmXLdafA2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Report: Gilead, GlaxoSmithKline mulling bids for United Therapeutics

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Six trends shaping the industries and sectors we cover in 2021


Report: Gilead, GlaxoSmithKline mulling bids for United Therapeutics

Gilead Sciences Inc. and GlaxoSmithKline plc are among suitors weighing bids for United Therapeutics Corp., the Evening Standard reported Aug. 4, citing anonymous sources.

The news outlet reported that Gilead is most likely to win a bid, while Novartis AG is another possible contender. According to the anonymous sources, United could be worth as much as $200 per share in a sale, making the purchase price around $8.7 billion.

GSK is being advised by Lazard and Citi in the process, the Evening Standard reported.